FACT 02 Delivers full-body benefits After meals, GLP-1 is released in the small intestine and travels through the body to affect receptors in the brain, stomach, pancreas, heart, and more
Exendin-4 reduces S-phase kinase associated protein 2 expression and upregulates p27Kip1 in a dose-dependent manner, inducing G0/G1 phase arrest in ALVA-41 cells and thereby suppressing proliferation (145)
Clinicians should actively screen at-risk patients by assessing liver enzymes (ALT, AST), calculating non-invasive scores like FIB-4, and using imaging when necessary
"I am interested in the cardiovascular protective effects of GLP-1 receptor agonists given my family history of heart disease" is a perfectly valid opening statement
Connect with a Klinic provider to talk through your options
However, most studies of pancreatic mass or exocrine cellular proliferation have reported no change with exenatide, liraglutide, or dulaglutide (86, 108, 109, 119, 121)
.png)
